SynthesisScientific reports2016
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.Human reproduction update · 2020Pooled it
- Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses.PloS one · 2018Pooled it
- Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.Journal of the American Heart Association · 2017Pooled it
- Trial
- Estimated glucose disposal rate as a candidate biomarker for thrombotic biomarkers in T1D: a pooled analysis.Journal of endocrinological investigation · 2021Trial
- Comparative analysis of obesity-related cardiometabolic and renal biomarkers in human plasma and serum.Scientific reports · 2019Trial
- Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.Metabolic syndrome and related disorders · 2017Trial
- Plasminogen Activator Inhibitor-1 is Internalized by Endothelial Cells via A Pinocytosis-Like Mechanism and Evades Degradation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Article
- A Narrative Review on Abnormalities in the Hemostatic System in Diabetes Mellitus: Pathophysiology, Clinical Implications, and Therapeutics.Life (Basel, Switzerland) · 2026Review
- Type 2 Diabetes Is Associated with Increased Coagulation Activity in Patients with Atrial Fibrillation: A D-Dimer-Based Analysis.Biomedicines · 2026Article
- Clot formation, structure, and fibrinolysis of plasma from pancreatic cancer patients.Journal of thrombosis and thrombolysis · 2025Article
- Cross-sectional and longitudinal association of seven DNAm-based predictors with metabolic syndrome and type 2 diabetes.Clinical epigenetics · 2025Article
- Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2025Article
- The Association Between HbA1c Levels And Hematological Biomarkers in Adults with Type 2 Diabetes Mellitus: A Retrospective Study.International journal of general medicine · 2025Article
- Endothelial dysfunction in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: current knowledge and novel biomarkers.Frontiers in endocrinology · 2025Review
- Review
- Associations of coagulation parameters and thrombin generation potential with the incidence of type 2 diabetes: mediating role of glycoprotein acetylation.European journal of epidemiology · 2024Article
- Associations between epigenetic aging and diabetes mellitus in a Swedish longitudinal study.GeroScience · 2024Article
- Blood PAI-1 and cardiovascular and metabolic risk factors among the middle-aged women from SWAN study.Scientific reports · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An emerging body of evidence has implicated plasminogen activator inhibitor-1 (PAI-1) in the development of type 2 diabetes (T2D), though findings have not always been consistent. We systematically reviewed epidemiological studies examining the association of PAI-1 with T2D. EMBASE, PubMed, Web of Science, and the Cochrane Library were searched to identify studies for inclusion. Fifty-two studies (44 cross-sectional with 47 unique analytical comparisons and 8 prospective) were included. In pooled random-effects analyses of prospective studies, a comparison of the top third vs. bottom third of baseline PAI-1 values generated a RR of T2D of 1.67 (95% CI 1.28-2.18) with moderate heterogeneity (I(2) = 38%). Additionally, of 47 cross-sectional comparisons, 34(72%) reported significantly elevated PAI-1 among diabetes cases versus controls, 2(4%) reported significantly elevated PAI-1 among controls, and 11(24%) reported null effects. Results from pooled analyses of prospective studies did not differ substantially by study design, length of follow-up, adjustment for various putative confounding factors, or study quality, and were robust to sensitivity analyses. Findings from this systematic review of the available epidemiological literature support a link between PAI-1 and T2D, independent of established diabetes risk factors. Given the moderate size of the association and heterogeneity across studies, future prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.